N-Phenylacetyl-L-prolylglycine ethyl ester

N-Phenylacetyl-l-prolylglycine ethyl ester is promoted as a nootropic and is a prodrug of cycloprolylglycine.[1] Other names include the brand name Noopept (Russian: Ноопепт), developmental code GVS-111; proposed INN omberacetam.[1][2][3]

N-Phenylacetyl-L-prolylglycine ethyl ester

Clinical data
Trade names	Noopept
Other names	N-Phenylacetyl-l-prolylglycine ethyl ester; GVS-111
Legal status
Legal status	US: Unscheduled Not FDA approved
Identifiers
IUPAC name Ethyl 1-(phenylacetyl)-l-prolylglycinate
CAS Number	157115-85-0 Y
PubChem CID	180496
ChemSpider	157065 N
CompTox Dashboard (EPA)	DTXSID80166214
Chemical and physical data
Formula	C17H22N2O4
Molar mass	318.367 g/mol g·mol−1
3D model (JSmol)	Interactive image
SMILES c2ccccc2CC(=O)N1CCC[C@@H]1C(=O)NCC(=O)OCC
InChI InChI=1S/C17H22N2O4/c1-2-23-16(21)12-18-17(22)14-9-6-10-19(14)15(20)11-13-7-4-3-5-8-13/h3-5,7-8,14H,2,6,9-12H2,1H3,(H,18,22)/t14-/m0/s1 N Key:PJNSMUBMSNAEEN-AWEZNQCLSA-N N
NY (what is this?)  (verify)

Its synthesis was first reported in 1996.[1] It is orally available, and as of 2017 its metabolism and elimination half-life were not well understood, as cycloprolylglycine had not been measured in humans following administration.[1]

As of 2017 there had been many studies conducted in cells and in animal models, and there had been one clinical trial with 41 subjects, which compared Noopept and piracetam in people with traumatic brain injury.[1]